Clinical Trials Browser

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Neoplasm Metastasis, Pancreatic Neoplasms, Endometrial Neoplasms

Pancreatic Acinar Cell Carcinoma

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

Fallopian Tube Neoplasms, Ovarian Neoplasms

Fallopian Tube Neoplasms, Neoplasms

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

Uveal Melanoma

Carcinoma, Renal Cell, Kidney Neoplasms

Lymphoma, Non-Hodgkin, Multiple Myeloma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms

Solid Tumors

Breast Neoplasms

Glioblastoma

Breast Neoplasms, Triple Negative Breast Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Pancreatic Neoplasms

Non-small-cell Lung Cancer Patients

Breast Neoplasms, Neoplasm Metastasis

Carcinoma, Ovarian Epithelial

Breast Neoplasms, Triple Negative Breast Neoplasms

Pancreatic Neoplasms

Fanconi Anemia, Complementation Group N, Fanconi Anemia, Complementation Group D1, Hereditary Sensory and Autonomic Neuropathies, Prostatic Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Neoplasm Metastasis

Cholangiocarcinoma

SCLC,Extensive Stage

Mesothelioma, Malignant, Lung Neoplasms, Mesothelioma

Advanced Breast Cancer

Platinum-sensitive Ovarian Cancer

Breast Neoplasms

Fanconi Anemia, Complementation Group D1, Breast Neoplasms, Triple Negative Breast Neoplasms

Fallopian Tube Neoplasms, Ovarian Neoplasms

Biliary Tract Neoplasms

Glioma, Cholangiocarcinoma

Ovarian Neoplasms

Pancreatic Neoplasms

Nasopharyngeal Carcinoma

Clinical Trials

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

TAPUR

Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma

ORCHID

CAPTUR

I-SPY

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

DAPA-ARMOR

Pembrolizumab, Olaparib, and Temozolomide for People With Glioma

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

Surgical Pembro +/- Olaparib w TMZ for rGBM

A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

Pembro With Radiation With or Without Olaparib

NePtune

Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.

Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab

ELEMENT

WoO

NeoADAPT

Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer

COBRA

PHOENIX

MOST plus

Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)

THOR

Olaparib in Patients With HRD Malignant Mesothelioma

Post-CDK

Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer

Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)

Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer

Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer

OPTIMUM

Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion

SOLID

STROBE

PALBOLA

DRUP

POINT